EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Higher Doses of Oral Propranolol for Resistant Infantile Haemangio­mas

Isabelle Dreyfus, Charlène Dénos, Olivia Boccara, Sébastien Barbarot, Véronique Gagey-Caron, Annabel Maruani, Juliette Miquel, Catherine Droitcourt, Michèle Bigorre, Ludovic Martin, Christine Leauté-Labrèze, Juliette Mazereeuw-Hautier

Acta Dermato-Venereologica · 2026

DOI: 10.2340/actadv.v106.43152 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2026. Verfasst von Isabelle Dreyfus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France. dreyfus.i@chu-toulouse.fr. Hauptthemen laut MEDLINE: Propranolol, Drug Resistance, Neoplasm, Adrenergic beta-Antagonists, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Propranolol at 3 mg/kg/day is considered the gold standard for treating infantile haemangiomas. Nevertheless, the management of propranolol-resistant infantile haemangiomas (PRIH) remains challenging. This national multicentre retrospective observational study includes all PRIHs who received propranolol > 3 mg/kg/day. The study aims to investigate the pattern of PRIHs, assess the effects and tolerance of a higher dose, and identify predictive factors for response to this increased dosage. Fifteen PRIHs were included (prevalence 0.45%), mainly females, and most presented with a large lesion. Three distinct patterns of PRIH were identified: facial segmental lesions (47%), facial localized lesions with a subcutaneous component (40%), and body-localized mixed and ulcerated lesions (13%). Six PRIH (40%) responded to the higher dose (from 3.75 to 4 mg/kg/day). Three predictive factors were significantly associated with a good response: IGIc-IH1 at the end of 3 mg/kg/day regimen (OR = 22.9, 95% CI [1.2–1844.1]), a duration of 3.5 months or more at 3 mg/kg/day (OR = 17.5, 95% CI [1.22–250.37]), and 7 months or more at > 3 mg/kg/day (OR = 17.5, 95% CI [1.22–250.37]). Tolerance was generally good, although one patient experienced severe hypotension during dose escalation. Propranolol doses higher than 3 mg/kg/day may therefore be considered a potential treatment option for PRIHs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololDrug Resistance, NeoplasmAdrenergic beta-AntagonistsSkin NeoplasmsHumansRetrospective StudiesFemaleInfantMaleAdministration, OralTreatment OutcomeTime Factors

Substanzen

PropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France. dreyfus.i@chu-toulouse.fr.
  • Reference Center for rare diseases of the skin, CHU Toulouse Larrey, Toulouse, France.
  • Dermatology Department, Necker Children's Hospital, Assistance publique-hôpitaux de Paris, Paris, France.
  • Department of Dermatology, Nantes Université, Nantes, France.
  • Dermatology Cabinet, Nantes, France.
  • Department of Dermatology, Unit of Pediatric Dermatology, University of Tours, Inserm 1246-SPHERE, CHRU Tours, Tours, France.

Zitieren

APA

Dreyfus, I., Dénos, C., Boccara, O., Barbarot, S., Gagey-Caron, V., Maruani, A., Miquel, J., Droitcourt, C., Bigorre, M., Martin, L., Leauté-Labrèze, C., & Mazereeuw-Hautier, J. (2026). Higher Doses of Oral Propranolol for Resistant Infantile Haemangio­mas. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v106.43152

Vancouver

Dreyfus I, Dénos C, Boccara O, Barbarot S, Gagey-Caron V, Maruani A, et al. Higher Doses of Oral Propranolol for Resistant Infantile Haemangio­mas. Acta Dermato-Venereologica. 2026. doi:10.2340/actadv.v106.43152

BibTeX
@article{Dreyfus2026,
  author = {Dreyfus, Isabelle and Dénos, Charlène and Boccara, Olivia and Barbarot, Sébastien and Gagey-Caron, Véronique and Maruani, Annabel and Miquel, Juliette and Droitcourt, Catherine and Bigorre, Michèle and Martin, Ludovic and Leauté-Labrèze, Christine and Mazereeuw-Hautier, Juliette},
  title = {Higher Doses of Oral Propranolol for Resistant Infantile Haemangio­mas},
  journal = {Acta Dermato-Venereologica},
  year = {2026},
  doi = {10.2340/actadv.v106.43152}
}
Kostenlos starten →